TÜBINGEN, Germany & BOSTON & SAN DIEGO–(BUSINESS WIRE)–CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA …
Tag Archives: Arcturus Therapeutics
January, 2018
October, 2017
-
20 October
Janssen and Arcturus Partner to Discover and Develop New Hepatitis B Drugs
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) — Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The two companies will work …
January, 2017
-
6 January
FDA Removes Full Clinical Hold On CTI BioPharma’s Pacritinib for Myelofibrosis
SEATTLE, Jan. 5, 2017 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. …
October, 2015
-
30 October
Ultragenyx and Arcturus Enter Potential $1.57 Billion RNA Collaboration
NOVATO, Calif., Oct. 29, 2015 /PRNewswire/ — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover …